Yuan Tian
Sichuan University(CN)Jinzhou Medical University(CN)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Gastrointestinal Tumor Research and Treatment, Metastasis and carcinoma case studies, Nutrition and Health in Aging, Inflammatory Biomarkers in Disease Prognosis
Most-Cited Works
- → Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study(2022)159 cited
- → HIF-1α Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a(2015)59 cited
- → Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial(2022)46 cited
- → Phase angle derived from bioelectrical impedance analysis as a marker for predicting sarcopenia(2022)44 cited
- → Predictive Effect of Systemic Immune-Inflammation Index Combined With Prognostic Nutrition Index Score on Efficacy and Prognosis of Neoadjuvant Intraperitoneal and Systemic Paclitaxel Combined With Apatinib Conversion Therapy in Gastric Cancer Patients With Positive Peritoneal Lavage Cytology: A Prospective Study(2022)40 cited
- → The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial(2020)37 cited
- → Combined systemic inflammatory immunity index and prognostic nutritional index scores as a screening marker for sarcopenia in patients with locally advanced gastric cancer(2022)36 cited
- → Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours(2022)33 cited
- → Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer(2021)32 cited
- → Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1 chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective study(2021)31 cited